错误:搜索内容不能为空,请输入英文关键词
错误:关键词超出字数限制,请精简
高级检索

The correlation between HOMA-IR and cardiometabolic risk index among different metabolic adults: a cross-sectional study

  • Qiyun Lu,
  • Benjian Chen,
  • Anxiang Li,
  • Qingshun Liang,
  • Jia Yao,
  • Yiming Tao,
  • Fangfang Dai,
  • Xiaoling Hu,
  • Jiayan Lu,
  • Yunwei Liu,
  • Yunyi Liu,
  • Yingxi Wang,
  • Jieer Long,
  • RongHua Zhang,
  • Zhenjie Liu

摘要

Aims

This study aimed to explore the correlation between homeostasis model assessment of insulin resistance(HOMA-IR)and cardiometabolic risk index(CMRI) among different metabolic adults to evaluate the value of HOMA-IR in predicting cardiometabolic risk.

Methods

This cross-sectional study was conducted over 18 months (from August 1, 2020 to February 18, 2022) and included 1550 participants divided into non-metabolic syndrome (non-MetS) group (n = 628) and metabolic syndrome (MetS) group (n = 922) in three centers of China. Logistic regression analysis was employed to investigate the correlation between HOMA-IR, body fat percentage, BMI (body mass index), visceral fat index, waist-to-hip ratio, vitamin D, and CMRI. Further analysis was conducted to evaluate the ability of HOMA-IR in diagnosing high CMRI within different metabolic, gender, and age groups to predict the risk of cardiovascular disease (CVD).

Results

HOMA-IR was significantly higher in the MetS group compared with the non-MetS group (P < 0.05). CMRI was significantly higher in the MetS group compared to the non-MetS group (P < 0.05). According to ROC curve analysis, HOMA-IR can predict cardiovascular risk (CVR) in the general population, non-MetS individuals, and MetS people. Logistic regression analysis revealed that BMI, visceral fat index, waist-to-hip ratio, and HOMA-IR are independent risk indicators of high CVR, whereas vitamin D may exert a protective role.

Conclusions

HOMA-IR was an independent risk factor for increased CVR in MetS patients. Moreover, HOMA-IR elevates the risk of CVD regardless of MetS and thus can be used for screening the general population.

Trial Registration

The study was registered at the Chinese Clinical Trial Registry (Registration Number: ChiCTR2100054654).